Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patientsÁngela Santonja, Emilio Alba, Arthur Jeiranian et al.|Cancer Research|2016Cited by 1